Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Down 39.7% in February

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the recipient of a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 4,100 shares, a drop of 39.7% from the January 31st total of 6,800 shares. Based on an average daily trading volume, of 33,300 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.3% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on Galmed Pharmaceuticals in a report on Tuesday. They set a “sell” rating on the stock.

Hedge Funds Weigh In On Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC acquired a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned approximately 3.97% of Galmed Pharmaceuticals at the end of the most recent quarter. 76.14% of the stock is currently owned by institutional investors and hedge funds.

Galmed Pharmaceuticals Trading Down 0.5 %

Shares of NASDAQ GLMD traded down $0.01 during midday trading on Tuesday, reaching $1.93. 134,393 shares of the company were exchanged, compared to its average volume of 690,991. Galmed Pharmaceuticals has a 1 year low of $1.63 and a 1 year high of $23.80. The stock has a fifty day simple moving average of $2.78 and a 200 day simple moving average of $3.57. The stock has a market cap of $1.24 million, a P/E ratio of -0.12 and a beta of 0.66.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.